SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
4.150
+0.110 (2.72%)
At close: Feb 20, 2026, 4:00 PM EST
4.230
+0.080 (1.93%)
After-hours: Feb 20, 2026, 7:59 PM EST
SLS Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
706.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.00M | -6.60M | -86.84% |
| Dec 31, 2021 | 7.60M | 5.70M | 300.00% |
| Dec 31, 2020 | 1.90M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 393.44M |
| Arvinas | 312.30M |
| Rigel Pharmaceuticals | 282.08M |
| Gyre Therapeutics | 107.27M |
| Kura Oncology | 104.03M |
| Fulcrum Therapeutics | 80.00M |
SLS News
- 5 weeks ago - SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe - GlobeNewsWire
- 7 weeks ago - SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 2 months ago - SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 - GlobeNewsWire
- 4 months ago - SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript - Seeking Alpha
- 4 months ago - SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds - GlobeNewsWire
- 6 months ago - Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026 - Seeking Alpha
- 7 months ago - SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification - GlobeNewsWire
- 8 months ago - SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board - GlobeNewsWire